All Oncology News

Luis E. Raez, MD, discusses major trials in squamous NSCLC and what lies ahead for immunotherapy.

Andrew D. Zelenetz, MD, PhD, discusses the use of emerging targeted therapies in mantle cell lymphoma.

Konstantinos Leventakos, MD, discusses updates in personalized medicine for patients with stage III lung cancer.

Paul Kelly Marcom, MD, discusses the role of genomic testing in breast cancer.

Thought leaders from NYU Langone’s Perlmutter Cancer Center highlight the latest groundbreaking breast cancer research being conducted at their institution.

The addition of the antibody-drug conjugate brentuximab vedotin and the PD-1 inhibitor nivolumab to chemotherapy in patients with stage I/II Hodgkin lymphoma is under investigation in an ongoing phase II trial (NCT03233347).

Wayne A. Marasco, MD, PhD, discusses the intricacy of engineering CAR T cells and the early data he has observed with CAR T-cell therapy in renal cell carcinoma.

The European Commission has approved larotrectinib for the treatment of certain adult and pediatric patients with solid tumors who have an NTRK gene fusion without a known acquired resistance mutation.

City of Hope shares recent research grants and awards given to faculty at the institution.

The FDA has expanded the approval of the noninvasive colorectal cancer (CRC) screening test Cologuard to include eligible at-risk individuals ≥45 years.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of gilteritinib as a single agent for the treatment of adult patients with relapsed/refractory acute myeloid leukemia who have FLT3 mutations.

The uptick of biosimilars has led to a surge of new data and regulatory decisions in recent years, with a focus on similarity between biosimilars and their reference products while reducing healthcare costs. This week, data on subcutaneous formulations of one biosimilar and long-term experience with another were provided, as well as an authorization of a trastuzumab (Herceptin) biosimilar in Canada.

Sarah M. Larson, MD, discusses trials with the potential to shift treatment strategies in the frontline and relapsed/refractory settings of multiple myeloma and remaining research questions in the field.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion to recommend approval of the combination of avelumab and axitinib for the frontline treatment of adult patients with advanced renal cell carcinoma.

Serial assessment of blood-based immune markers showed that the risk of progression from monoclonal gammopathy of undetermined significance, the precursor disease to multiple myeloma is fluctuating rather than determinate, and these patients can experience progression to myeloma within 5 years.

Gary J. Schiller, MD, discusses therapeutic advances, the importance of genomic testing, and other agents in the pipeline for acute myeloid leukemia.

Gastrointestinal oncology experts highlight what they are most excited for at the upcoming International Society of Gastrointestinal Oncology 16th Annual Gastrointestinal Oncology Conference.

Arek Z. Dudek, MD, PhD, discusses the research surrounding osimertinib in the treatment of patients with EGFR-positive non–small cell lung cancer.

Herbert A. Eradat, MD, explains how insight into the pathogenesis of chronic lymphocytic leukemia is leading to novel treatment strategies and shed light on unmet needs in the field.

Sylvia Adams, MD, discusses the biology of triple-negative breast cancer, data sparking excitement in the field, and intriguing trials on the horizon.

Christopher S. Seet, MD, PhD, discusses elements of treatment discontinuation in chronic myeloid leukemia.

Leonard G. Gomella, MD, FACS, discusses the role of genetic testing and emerging biomarkers in prostate cancer.

David Bond, MD, addresses the ongoing challenge of second primary neoplasia in chronic lymphocytic leukemia.

Michael Wang, MD, discusses how the mantle cell lymphoma paradigm is facing a time of exploration, as researchers examine different therapeutic options beyond chemotherapy.

Patients with metastatic colorectal cancer who harbored BRAF non-V600, RAS-dependent mutations were more likely to respond to anti-EGFR therapy versus those with BRAF non-V600, RAS-independent mutations.

The FDA has approved apalutamide for the treatment of patients with metastatic castration-sensitive prostate cancer.

The combination of cabazitaxel in combination with carboplatin demonstrated an improvement in progression-free survival versus cabazitaxel alone in men with metastatic castration-resistant prostate cancer.

Although several newer JAK inhibitors are being investigated, such as pacritinib, momelotinib, and the recently FDA-approved fedratinib, most combinations are being explored in combination with ruxolitinib.

The International Society of Gastrointestinal Oncology, a not-for-profit global educational organization committed to gastrointestinal oncology, will host the 16th Annual Gastrointestinal Oncology Conference from Oct. 10-11, 2019 at the Hilton Crystal City in Arlington, Virginia.

The FDA has granted an accelerated approval to the combination of lenvatinib and pembrolizumab for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high or mismatch repair deficient, and who have disease progression following prior systemic therapy but are ineligible for curative surgery or radiation.